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Mitochondria are well appreciated for their role as biosynthetic and bioenergetic organelles. In the past two
decades, mitochondria have emerged as signaling organelles that contribute critical decisions about cell
proliferation, death, and differentiation. Mitochondria not only sustain immune cell phenotypes but also
are necessary for establishing immune cell phenotype and their function. Mitochondria can rapidly switch
from primarily being catabolic organelles generating ATP to anabolic organelles that generate both ATP
and building blocks formacromolecule synthesis. This enables them to fulfill appropriatemetabolic demands
of different immune cells. Mitochondria havemultiple mechanisms that allow them to activate signaling path-
ways in the cytosol including altering in AMP/ATP ratio, the release of ROS and TCA cyclemetabolites, aswell
as the localization of immune regulatory proteins on the outer mitochondrial membrane. In this Review, we
discuss the evidence and mechanisms that mitochondrial dependent signaling controls innate and adaptive
immune responses.Introduction
Over the last 30 years, the molecular events that drive immune
responses have been characterized in great detail in numerous
cell types. A successful immune response requires a delicate
balance of activation and inhibition of distinct signaling pathways
in diverse cell types. Classically, these signaling pathways are
conceptualized as linear phosphorylation-based cascades initi-
ated at the cell surface and transmitted to the nucleus. However,
increasing data suggest that many of these signaling pathways
are highly integrated with cellular metabolism, which not only
fuels active cells but also provides guidance for cell-fate deci-
sions. These studies have led to the creation of the new field of
investigation termed immunometabolism.
For decades, we have observed that immune cells transform
from a state of relative metabolic quiescence to a highly active
metabolic state during the activation phase of an immune
response. Predictably, this conversion requires a shift in cellular
metabolism from a catabolic to an anabolic metabolic program
(Pearce and Pearce, 2013). In a catabolic state, macromolecules
are completely degraded and shuttled through energy-gener-
ating pathways to produce ATP to maintain cellular homeostasis
and allow long-term survival during quiescence. Alternatively, in
an anabolic state, cellular metabolism is reorganized to balance
a need for ATPwith the need formetabolic intermediates that are
required for de novo synthesis of macromolecules. Yet our lab
and others have observed that during both catabolism and anab-
olism, metabolic pathways provide more than just ATP and
biosynthetic intermediates and importantly provide signaling in-
termediates that are essential for cellular function. An emerging
concept is that metabolism not only sustains diverse immune
cell phenotypes as a consequence of alterations in cellular
signaling, but metabolism also feeds back and alters signaling
to drive immune-cell phenotypes. Mitochondria are central
hubs of metabolism that thus have emerged to be necessary
for both the maintenance and establishment of immune cell406 Immunity 42, March 17, 2015 ª2015 Elsevier Inc.phenotypes. In this review, we will create a conceptual frame-
work to establish mitochondria as signaling organelles that are
critical for innate and adaptive immune responses.
Mitochondria are Bioenergetic, Biosynthetic, and
Signaling Organelles
Historically, the major role of mitochondria is thought to be to the
efficient coupling of metabolite oxidation through the tricarbox-
ylic acid (TCA) cycle to ATP production by the electron transport
chain (ETC). Fatty acids or pyruvate are oxidized into acetyl-CoA
by fatty-acid oxidation or pyruvate dehydrogenase (PDH),
respectively. Subsequently, the TCA cycle is initiated by the
enzyme citrate synthase that catalyzes the condensation reac-
tion of acetyl-CoA with oxaloacetate to generate citrate. The
TCA cycle generates reducing equivalents NADH and FADH2
that provide electrons to the electron transport chain. The ETC
complexes ultimately transfer electrons to molecular oxygen
and concomitantly pump protons across the inner mitochondrial
membrane resulting in a generation of a proton-motive force that
is utilized to produce ATP by the FoF1 ATP synthase. Mitochon-
dria that fail to generate a mitochondrial membrane potential
are targeted for destruction through mitophagy. Mitochondrial
oxidation of pyruvate and fatty acids such as palmitate gener-
ates 31.5 and 113 ATP, respectively, compared to 2 ATP gener-
ated by glycolysis (Mookerjee et al., 2015). Thus, mitochondria
are the most efficient source of cellular ATP (Figure 1).
An equally important primordial function of mitochondria is the
utilization of TCA cycle metabolites for the building of macromol-
ecules (Figure 1). For example, citrate can be transported into
the cytosol where ATP-citrate lyase (ACLY) converts citrate
into acetyl-CoA and oxaloacetate. Cytosolic acetyl-CoA is
utilized for protein acetylation, as well as de novo fatty-acid syn-
thesis (Wellen and Thompson, 2012). Citrate depletion from the
TCA cycle for de novo lipid synthesis necessitates replenishment
of the TCA cycle (termed anaplerosis) to allow it to continue
Figure 1. Mitochondria Are Essential
Metabolic and Signaling Organelles
Cytosolic metabolic pathways funnel into the
mitochondria where they constantly replenish the
TCA cycle. Depending on the cellular metabolic
state, TCA cycle intermediates can be further
oxidized to generate ATP (blue) or they can be
shuttled out of the mitochondria into subsidiary
pathways to generate cellular building blocks such
as fatty acids (purple). Finally, TCA cycle metab-
olites (orange) in addition to other byproducts of
mitochondrial metabolism, such as ROS, function
as important signaling molecules that control
cellular functions.
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minolysis, which results in the generation of a-ketoglutarate
(Hensley et al., 2013).
These two functions of mitochondria to generate ATP and to
support biosynthesis must be carefully balanced to support spe-
cific cellular demands. Thus, mitochondria are metabolic hubs
within the cell that alter their function to meet cellular needs.
Clearly this necessitates that mitochondria receive signals to
change their function. But importantly, more and more data sug-
gest that mitochondrial pathways are not just reactive but also
actively provide signals back to the nucleus. This crosstalk might
coordinate cell-fate decisions with metabolic capacity depen-
dent on the cellular environment. Thus we propose that mito-
chondria are crucial cellular signaling organelles that are an inte-
gral part of the decision-making process when cells receives
internal and external cues to trigger diverse biological outcomes
ranging from metabolic adaptation, proliferation, differentiation,
and cell death (Chandel, 2014).
There are several known types of signal transduction mecha-
nisms between mitochondria and the rest of the cell (Figure 1).
First, anterograde signaling is signal transduction from cytosol
to mitochondria. The best example of this is the rapid seques-
tration of calcium into the mitochondrial matrix in response to
elevations in cytosolic calcium (Rizzuto et al., 2012). The influx
of calcium into the mitochondria results in activation of multiple
enzymes of the TCA cycle and the ETC. Second, retrograde
signaling is signal transduction from mitochondria to the
cytosol. One of the earliest examples of retrograde signaling
was the production of mitochondrial reactive oxygen species
(ROS) regulating the activation of the transcription factor hypox-
ia inducible factor 1 (HIF-1) (Chandel et al., 1998). Recent
studies indicate that mitochondrial ROS regulate metabolic
adaptation, differentiation, and proliferation (Sena and Chandel,
2012). The ETC can produce superoxide, notably from com-
plexes I and III, that can be converted into hydrogen peroxide
and released into the cytosol where it can cause thiol oxidation
of proteins (Murphy, 2009). There are a total of ten potential
sites of ROS generation within mitochondria (Quinlan et al.,
2013). Mitochondria can also impact signaling by altering theImmunity 4availability of TCA cycle intermediates
acetyl-CoA, succinate, fumarate, and a-
ketoglutarate, which can alter protein
function (Metallo and Vander Heiden,
2010). Acetyl-CoA is utilized for protein
acetylation, a-ketoglutarate is required
for function of a-ketoglutarate-dependent dioxygenases family
of proteins, which include the prolyl hydroxlylaseas (PHDs)
and Jumonji domain-containing histone demethylase (JHDM),
and fumarate and succinate are inhibitors of these proteins
(Kaelin and McKnight, 2013). PHDs and JHDM are negative
regulators of the HIFs and are also sensitive to hydrogen
peroxide. As such, the accumulation of fumarate, succinate,
and hydrogen peroxide can result in inactivation of PHDs and
JHDMs resulting in activation of HIFs and hypermethylation of
histones. Mitochondrial bioenergetic status can also influence
signaling pathways. Notably, the decrease in mitochondrial
ATP production typically increases AMP concentrations that
cause a shift from an anabolic state to a catabolic state to sus-
tain high ATP/ADP ratio necessary to thermodynamically favor
ATP coupled reactions. The increase in AMP/ATP ratio triggers
activation of AMP-activated protein kinase (AMPK) that de-
creases mammalian target of rapamycin (mTOR) activity to
diminish anabolic reactions thus reducing ATP demand and
activate autophagy to increase metabolic supply by providing
nutrients to mitochondria for generation of ATP (Pearce et al.,
2013). AMPK activation also promotes fatty-acid oxidation while
suppressing fatty-acid synthesis. Lastly, the outer mitochondrial
membrane is known to serve as a signaling platform to align
multiple proteins to allow for coordinated interaction and subse-
quent signaling (West et al., 2011a).
Mitochondrial Signaling Dictates Macrophage
Polarization and Function
Macrophages are commonly distinguished into two lineages,
classically activated (M1) and alternatively activated (M2). M1
macrophages display marked production of inflammatory medi-
ators following exposure to pro-inflammatory mediators such as
LPS while M2 polarized macrophages display a pro-fibrotic and
anti-inflammatory signature in response to the cytokine inter-
leukin-4 (IL-4). Although this classification scheme is imperfect
and there almost certainly exists many more macrophage sub-
types, it is a useful model for studying how metabolism differs
in macrophages with differing functions (Mosser and Edwards,
2008). M1 polarized macrophages exhibit robust glycolysis2, March 17, 2015 ª2015 Elsevier Inc. 407
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consumption compared to unpolarized macrophages, suggest-
ing minimal reliance on mitochondrial metabolism and a depen-
dence on glycolytic ATP production compared with the M0
unpolarized macrophages (Haschemi et al., 2012; Huang et al.,
2014). In contrast, M2 polarized macrophages demonstrate an
increase in oxygen consumption. The importance of these differ-
ence in mitochondrial metabolism between M1 and M2 in vivo is
supported by the finding that mice deficient in NDUFS4, a sub-
unit of complex I of the ETC, exhibit an enhancedM1 polarization
and diminished M2 polarization (Jin et al., 2014).
The induction of M2 polarization is driven by IL-4 stimulation of
signal transducer and activator of transcription 6 (STAT6) result-
ing in PPARg-coactivator-1b (PGC-1b) induction of mitochon-
drial biogenesis and fatty-acid oxidation (Vats et al., 2006). The
carnitine palmitoyltransferase-1 (CPT1) inhibitor etomoxir, which
inhibits fatty-acid translocation into the mitochondria, is suffi-
cient to inhibit expression of classic M2 genes indicating that
the increase in mitochondrial metabolism is not simply an effect
of STAT6 activation needed for sustaining theM2phenotype, but
is in fact a driver of M2 macrophage activation and function.
Furthermore, the loss of the transcription factors of the peroxi-
some proliferator-activated receptor (PPAR) family, transcription
factors known to activate oxidative metabolism in numerous tis-
sues, leads to a deficit in M2 polarization (Kang et al., 2008; Ode-
gaard et al., 2007, 2008). In contrast, overexpression of PGC-1b
promotes M2 polarization that could be reversed following phar-
macologic blockade of fatty-acid oxidation or mitochondrial ATP
production (Vats et al., 2006). These data are consistent with the
observation that M2macrophages require AMPK, a stimulator of
fatty-acid oxidation, for proper activation in vivo (Mounier et al.,
2013) (Carroll et al., 2013). Interestingly, the potential source of
fatty acids required for M2 polarization is internal lysosomal
stores. Thus, M2 macrophages require cell autonomous lyso-
somal-based lipolysis to increased internal fatty acids to fuel
the enhanced mitochondrial metabolism (Huang et al., 2014).
Going forward it will be important to specifically ablate fatty-
acid oxidation or lysosomal-dependent lipolysis in macrophages
to confirm in vivo significance lysosomal-dependent lipolysis
and fatty-acid oxidation in establishing and maintaining the M2
phenotype.
A critical question that remains unanswered is what are the ad-
vantages of conducting enhanced glycolysis and mitochondrial
metabolism in establishing the M1 and M2 phenotype, respec-
tively? A clue might come from the observation that M1 macro-
phages require glucose-dependent metabolism for anabolic
functions, whereas the role of mitochondria is restricted to sig-
naling organelles in response to microorganism-derived path-
ogen-associated molecular patterns (PAMPs) and endogenous
tissue injury-derived damage-associated molecular patterns
(DAMPs).
Mitochondrial Signaling Is Necessary for Responses to
Activators of Innate Immune Signaling
Pathogen-associated molecular patterns (PAMPs) and damage-
associate molecular patterns (DAMPs) bind to specific recep-
tors, including RIG-I-like receptors (RLRs), NOD-like receptors
(NLRs), and Toll-like receptors (TLRs), to generate cytokines
that are essential for eliminating pathogens or repairing tissue408 Immunity 42, March 17, 2015 ª2015 Elsevier Inc.damage. Interestingly, mitochondrial DNA and N-formyl pep-
tides represent two sources of mitochondrial DAMPs that acti-
vate pattern-recognition receptors (PRRs). N-formyl-methionine
is the initiating residue for both mitochondria and bacterial pro-
tein synthesis. Bacterial N-formyl peptides serve as PAMPs by
activating G-protein-coupled formyl peptide receptors (FPRs)
(Rabiet et al., 2007), and mitochondrial N-formyl peptides act
as DAMPs through activation of the receptor FPR-1 to stimulate
cytokine secretion (Carp, 1982; Zhang et al., 2010). Mitochon-
drial DNA is similar to bacterial DNA in that both share hypome-
thylated CpG motifs, which activate TLR9 (West et al., 2011a).
Direct injection of mitochondrial (but not nuclear) DNA into
mouse joints induces a pro-inflammatory response (Collins
et al., 2004), and systemic injection of mitochondrial DNA in-
duces lung and liver inflammation (Zhang et al., 2010). Mitochon-
drial DNA is also released systemically during trauma injury to
induce inflammation (Zhang et al., 2010). Thus, mitochondrial
DAMPS drive hyperactivation of innate immunity in an absence
of an infection by a microorganisms i.e., sterile inflammation. In
the next section we review the evidence for mitochondria-
dependent signaling in regulating responses to both DAMPs
and PAMPs.
Initial studies implicating mitochondria as signaling organelles
in innate immunity came from the observations that LPS through
TLR4 and tumor necrosis factor-a (TNF-a) through TNF receptor
associated factors (TRAFs) activate inflammatory cytokines
through the generation of mitochondrial generated ROS (Chan-
del et al., 2000, 2001). More recent studies have shown that
decreasing mitochondrial ROS diminishes multiple TLR-initiated
pathways and bactericidal activity of macrophages (West et al.,
2011b). TLR1, 2, and 4 activation results in mitochondrial trans-
location of TRAF6 that interacts with ECSIT, a protein that has
been implicated in mitochondrial respiratory complex I assem-
bly, leading to increased mitochondrial ROS that aid in the
destruction of phagocytosed bacteria. It is not clear how ECSIT
regulates mitochondrial ROS production upon TLR stimulation.
Furthermore, patients with tumor necrosis factor receptor-asso-
ciated periodic syndrome (TRAPS) have heightened responsive-
ness to LPS due to increasedmitochondrial ROS production that
promotes inflammation (Bulua et al., 2011).
Aside from ROS, the TCA cycle intermediate succinate has
also been implicated in LPS-induced inflammatory cytokine
signaling (Figure 2). In the TCA cycle, succinate is produced
from succinyl-CoA and subsequently converted to fumarate by
succinate dehydrogenase. Succinate dehydrogenase is the
only TCA enzyme that also functions as an electron carrier in
the electron transport chain, which might position it to also
modulate ROS signaling (Mills and O’Neill, 2014). In LPS-acti-
vated macrophages, increases in succinate concentrations sta-
bilize HIF-1a through inhibition of PHDs (Tannahill et al., 2013),
an effect that has previously been reported to occur in tumors
(Selak et al., 2005). This stabilization of HIF-1a induces the
expression of the pro-inflammatory cytokine IL-1b. In addition
to directly activating HIF-1 through PHD inactivation, succinate
might also increase mROS production, which is known to acti-
vate HIF-1a in macrophages (Wang et al., 2010). Interestingly,
a recent study demonstrated that succinate buildup results in
increased reverse electron transport and ROS production from
complex I of the ETC (Chouchani et al., 2014). Going forward,
Figure 2. Mitochondria Are Critical to
Activation of the Immune Response
Mitochondrial components such as mitochondrial
DNA (mtDNA) and N-formyl peptides can act as
damage-associated molecular patterns (DAMPs).
Specifically, mtDNA can activate the NLRP3 in-
flammasome and TLR9 to induce an inflammatory
response, while N-formyl peptides activate pro-
inflammatory gene expression through the N-
formyl peptide receptor-1 (FRP1). In addition to
production and presentation of DAMPs, mito-
chondrial metabolism and signaling further pro-
mote the induction of inflammation to pathogens.
Mitochondrial-derived metabolites such as mROS
and succinate enhance pro-inflammatory gene
expression, and mROS also can function directly
as an anti-microbial effector molecule and NLRP3
activator. Additionally, mitochondrial localized
proteins and lipids, MAVS, and cardiolipin res-
pectively, are required for proper activation of the
NRLP3 inflammasome. Finally, cellular calcium
flux is linked to NLRP3 activation and mitochon-
drial function and signaling.
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sults in accumulation of succinate and whether succinate activa-
tion of IL-1b expression requires mitochondrial ROS. Citrate is
another TCA cycle intermediate implicated in LPS activation of
pro-inflammatory gene expression. It is known that it is exported
from the mitochondria to the cytosol and converted to acetyl-
CoA; however, the precise mechanism by which it thereby alters
cytokine production is unclear (Infantino et al., 2011).
In addition to TLRs, other PRRs are known to depend on
mitochondrial ROS signaling including nuclear oligomerization
domain (NOD)-like receptors (NLRs) (Figure 2). Upon activation,
NLRs form multi-subunit protein complexes termed inflamma-
somes that activate caspase-1, resulting in proteolytic cleavage
andmaturation of the pro-inflammatory cytokine IL-1b (Schroder
and Tschopp, 2010). Diverse PAMPs and DAMPs such as lipo-
polysaccharide (LPS), asbestos, ATP, and uric acid lead to
NLRP3 activation through increase in ROS (Cruz et al., 2007;
Dostert et al., 2008). Specifically, pharmacological manipula-
tions resulting in diminished mitochondrial ROS decrease
NLRP3 inflammasome activation, but not other inflammasome
subsets (Zhou et al., 2011). Furthermore, pharmacologic or ge-
netic blockade of autophagy, which increases mitochondrial
ROS concentrations, enhances inflammasome activation (Saitoh
et al., 2008; Zhou et al., 2011). The release of mitochondrial ROS
leads to lysosomal membrane permeabilization necessary for
proper NLRP3 activation (Heid et al., 2013). A consequence of
NLRP3 activation is the induction of mitochondrial damage
with concomitant block in mitophagy to remove damaged mito-
chondria (Yu et al., 2014). Apart frommitochondrial ROS, release
of mitochondrial DNA (mtDNA) into the cytosol was found to
enhance NLRP3 activation (Nakahira et al., 2011). Later it was
shown that oxidized mtDNA is actually required to activate
NLRP3 (Shimada et al., 2012). This finding is provocative
because it suggests that mtDNA is released from mitochondria
without release of cytochrome c and induction of cell death.
Further study of this observation is likely to reveal newmitochon-
drial transport mechanisms. Another recent finding linking mito-chondria to NLRP3 is the observation that cardiolipin on the
mitochondrial outer membrane directly binds to NLRP3 resulting
in its activation (Iyer et al., 2013). Importantly, although many
studies suggest an important role of mitochondrial ROS, cardio-
lipin, and DNA for in regulating NLRP3 activation, direct genetic
evidence is still lacking in vivo.
It is important to note that mitochondrial ROS are necessary
for optimal activation of NLRP3 inflammasome as other key ac-
tivators such as influx of calcium and potassium efflux are also
major regulators of NLRP3 inflammasome (Gurung et al.,
2014). Calcium influx also contributes to mitochondrial damage
which might increase mitochondrial ROS and release of mito-
chondrial DNA to amplify NLRP3 inflammasome activation (Mur-
akami et al., 2012). The specific mechanisms by which diverse
PAMPs and DAMPs increase mitochondrial ROS and by which
mitochondrial ROS and ions such as calcium cooperate to opti-
mally activate NLRP3 have yet to be delineated.
An emerging theme in the past decade is that the mitochon-
drial outer membrane serves as a signaling platform for innate
immune responses. The most studied example of this is a class
of PRRs that respond to viral infection known as the retinoic-
acid-inducible protein I (RIG-I)-like receptor family (RLRs). The
three members of RLRs are RIG-I, MDA5 and DHX58 that func-
tion in antiviral immunity by sensing viral 50-triphosphorylated
and uncapped single- or double-stranded RNA resulting in the
production of type I interferons and pro-inflammatory cytokines
(Reikine et al., 2014). A breakthrough in establishing the role
for mitochondria in RLR-activated antiviral immunity was the
identification of the RLR mitochondrial adaptor protein MAVS
(mitochondrial antiviral-signaling protein)(Kawai et al., 2005;
Meylan et al., 2005; Seth et al., 2005; Xu et al., 2005) localization
to the outer mitochondrial membrane is indispensable for its
function. MAVS contains a C-terminal transmembrane domain,
which targets the protein to the outer membrane of mitochon-
dria (Figure 3). Subsequent studies demonstrated that MAVS
does not bind to free mitochondria but to mitochondrial associ-
ated membrane (MAM), which physically connects endoplasmicImmunity 42, March 17, 2015 ª2015 Elsevier Inc. 409
Figure 3. The Mitochondria Are Essential
for the Proper Induction of Antiviral
Signaling
The mitochondrial antiviral signaling protein
(MAVS) is required for proper induction of RLR
mediated activation of antiviral immunity. Impor-
tantly, mitochondrial dynamics, membrane po-
tential, and ROS production are critical regulators
of MAVS signaling. MAVS also localizes to the
peroxisome, an organelle with a well described
role in fatty-acid oxidation and H2O2 generation.
Stimulation of peroxisomal MAVS signaling in-
duces IFN-l1 production through IRF1 activation,
while mitochondrial-localized MAVS drives IFN-b
and IFN-l1 production. Along with MAVS, the
mitochondrial also function as an activator of the
stimulator of interferon genes protein (STING).
Specifically, mtDNA translocated to the cytoplasm
activates cyclic GMP-AMP synthase (cGAS),
which triggers STING signaling, which further en-
hances antiviral immunity.
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brane (Horner et al., 2011). MAM provides a mitochondrial/ER
inter-organelle communication that regulates stress and meta-
bolic signaling (Hayashi et al., 2009). Mice deficient in MAVS
are impaired in their ability to produce type I IFNs and thus are
highly susceptible to RNA virus infection (Sun et al., 2006).
RIG-I and MDA5 interact with MAVS through mutual caspase
activation and recruitment domains (CARDs) upon recognition
of viral RNA. Subsequently, RIG-I interaction with MAVS induces
prion-like aggregates of MAVS on the outer mitochondrial mem-
brane leads to activation of downstream pathways such as
interferon regulatory factor 3 (IRF3), MAP kinases, and nuclear
factor-kB (NF-kB) (Hou et al., 2011).
It is important to note that MAVS is also localized to the mem-
branes of peroxisomes, which is necessary for the rapid early but
transient expression of antiviral genes called interferon-stimu-
lated genes (ISGs) (Dixit et al., 2010). Furthermore, mitochondrial
MAVS induces both IFN-b and IFN-l while peroxisomal MAVS
induces IFN-l in a interferon regulatory factor 1 (IRF1)-depen-
dent manner (Odendall et al., 2014). Thus, maximal antiviral
response requires the coordination of both mitochondrial and
peroxisomal MAVS (Figure 3). Peroxisomes like mitochondria
carry out oxidation of fatty acids and generate ROS (Lodhi and
Semenkovich, 2014). Peroxisomes also exchange proteins with
mitochondria (Camo˜es et al., 2009). Given the shared roles in
ROS and lipidmetabolism between the two organelles, we spec-
ulate that MAVS recruitment to mitochondrial and peroxisomal
membranes could be related to lipid and/or ROS metabolism.
Indeed peroxisomal lipid synthesis can regulate immune cells
as highlighted by the recent finding that loss of PexRAP, a perox-410 Immunity 42, March 17, 2015 ª2015 Elsevier Inc.isomal enzyme required for ether lipid
synthesis, results in neutropenia (Lodhi
et al., 2015).
MAVS activation is also regulated by
mitochondrial dynamics. Healthy mito-
chondria displaying robust mitochon-
drial membrane potential are in a fused
network, whereas fission is indicative
of damaged depolarized mitochondria.
Multiple studies have demonstrated thatmitochondrial fusion promotes, whereas mitochondrial fission
inhibits RLR signaling (Castanier et al., 2010; Yasukawa et al.,
2009; Zhao et al., 2012). Further strengthening this link, mito-
chondrial membrane potential alone is required for proper induc-
tion of antiviral signaling (Koshiba et al., 2011). It is unclear
why mitochondrial dynamics dramatically influences antiviral
signaling. Moreover, the central question as to why mitochon-
drial localization is necessary for MAVS to propagate RIG-I
signaling remains unanswered. A speculative idea is that initia-
tion of MAVS aggregation requires a lipid or protein component
in the outer mitochondrial membrane. Alternatively, mitochon-
dria might release protein, lipids, metabolites, or ROS necessary
for optimal MAVS dependent antiviral signaling. Indeed, mito-
chondrial ROS have been shown to enhance MAVS mediated
antiviral signaling (Tal et al., 2009; Zhao et al., 2012). Interest-
ingly, MAVS is also necessary for NLRP3 activation (Subrama-
nian et al., 2014). Future experiments will have to delineate the
mechanisms by which outer mitochondrial membrane as a
signaling platform controls innate immune responses.
The induction of type I IFNs can also be invoked by release of
mitochondrial DNA. Two recent studies demonstrate that Bak-
and Bax-mediated mitochondrial damage in the absence of acti-
vating the downstream apoptotic caspases triggers the release
of mitochondrial DNA (mtDNA), which cyclic GMP-AMP syn-
thase (cGAS)/STING-mediated cytosolic DNA sensing pathway
(Rongvaux et al., 2014; White et al., 2014). DNA binding to
cGAS catalyzes the production of cyclic GMP-AMP dinucleotide
(cGAMP), which binds to and activates STING resulting in
induction of type I IFN transcription via the Tbk1-Irf3 signaling
axis (Barber, 2014). STING localizes to endoplasmic reticulum
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Zhong et al., 2008). It remains to be tested whether there are
physiological and pathological conditions where mitochondrial
DNA is released without mitochondrial damage to increase
IFN-b expression. There is precedent that mitochondria can
transport proteins and lipids through small vesicular carriers (Su-
giura et al., 2014).
Aside from macrophages, other important antigen-presenting
cells are dendritic cells (DCs). Upon exposure to antigen, DCs
rapidly increased their phagocytic capacity while simultaneously
elevating expression of major histocompatibility complex I (MHC
I) and MHC II. This process, termed DC maturation, also pro-
motes migration of DCs to the T cell zones of the secondary im-
mune organs and is required for proper activation and control of
an adaptive immune response (Joffre et al., 2009). The activation
of this program using TLR stimulation results in a robust increase
in glycolytic flux in dendritic cells (Everts et al., 2012; Krawczyk
et al., 2010). This alteration in metabolism is required to meet
the increased bioenergetic and biosynthetic demands of an acti-
vated DC, specifically by funneling metabolites into pathways for
lipid and protein synthesis (Everts et al., 2014). Other studies
have correlated increased intracellular lipid concentrations in
DCs with enhanced antigen presentation and polarization of
T cells toward inflammatory lineages, suggesting that the rate
of de novo fatty-acid synthesis might regulate the immunoge-
nicity of dendritic cells (Ibrahim et al., 2012). Emerging data
has recently demonstrated that dendritic cells can be grouped
into distinct subsets that display unique characteristics, similar
to macrophages and T cells. As with macrophages, DCs likely
exist in numerous different subsets however for simplicity that
are classically designated as either an immunogenic or tolerant
subset. Immunogenic DCs display high phagocytic activity and
MHC expression after activation and are thought to drive inflam-
matory T cell responses (Everts et al., 2014). In contrast, tolero-
genic DCs are characterized by a resistance to maturation along
with the expression of immune-modulatory factors, which corre-
sponds to an increased T regulatory cell (Treg) response (Pulen-
dran et al., 2010). New data suggest that tolerogenic DCs display
a high levels of fatty-acid oxidation and low levels of glycolysis
reminiscent of the anti-inflammatory M2 macrophage (Cook
et al., 2012; Ferreira et al., 2012; Szanto et al., 2010) DCs lacking
PPAR-g show increased immunogenicity while simultaneously
failing to induce tolerogenic T cell responses (Klotz et al.,
2007), further promoting a link between fatty-acid oxidation
and a suppressive immune phenotype. Future studies need to
further explore how metabolism differs in different subsets of
DCs, and whether alterations in metabolism specifically in these
cells is necessary to activate the transcriptional networks that
establish these subsets.
Mitochondrial Signaling Controls Adaptive Immunity
T cells respond to antigens and therefore are central orchestra-
tors of adaptive immune responses. During infection, naive
T cells (Tn) challenged with an antigen rapidly proliferate into
effector T cells (Te). The majority of Te cells undergo cell death
with a few long-lived memory T cells (Tm) after the infection di-
minishes. Tm cells can be reactivated into rapidly expanding
into Te cells if a similar infection occurs to quickly curtail
the infection. There also exist active immunosuppressive cellstermed regulatory T cells (Tregs) that suppress proliferation
and function of effector T cells. These T cells subtypes have
different metabolic demands and functions therefore exhibit
diverse metabolic profiles. Aberrant T cell function results in a
myriad of pathologies including auto-immune diseases.
Mitochondrial ROS Regulate T Cell Activation
Antigen stimulation of the T cell receptor (TCR) along with
engagement of co-stimulatory molecules on naive T cells shifts
them from a quiescent catabolic state in which nutrients are uti-
lized to generate ATP required for cellular survival to a robust
anabolic state where nutrients feed into metabolic pathways
that generate macromolecules necessary for cell proliferation.
Classical studies demonstrate that the anabolism of activated
T cells is supported by large increases in glucose consumption
that feed into multiple pathways. More recent studies indicate
that glutamine is also an important fuel source, which supports
mitochondrial metabolism through glutaminolysis (Carr et al.,
2010; Sinclair et al., 2013). The transcription factor myc is
necessary for this increased mitochondrial flux (Wang et al.,
2011). Pharmacologic inhibition of mitochondrial oxidative
phosphorylation or glycolysis in vitro diminishes T cell prolifera-
tion indicating that mitochondrial metabolism and glycolysis
support T cell proliferation (Chang et al., 2013; Sena et al.,
2013). However, glycolysis but not mitochondrial metabolism
is dispensable for T cell activation and production of the cyto-
kine IL-2 prior to proliferation (Sena et al., 2013) (Figure 4). In
fact, mitochondrial metabolism was found to be required for
T cell activation through generation of mitochondrial ROS
necessary for optimal activity of NFAT, NF-kB, and proximal
TCR signaling (Gill and Levine, 2013; Kaminski et al., 2010; Ka-
minski et al., 2012; Sena et al., 2013). It is known that mitochon-
drial localization to the immune synapse is required for T cell
activation (Contento et al., 2010; Martı´n-Co´freces et al., 2014;
Quintana et al., 2007), likely for efficiency of both calcium and
ROS signals. Future studies will more clearly define the mito-
chondrial ROS molecular target in T cell activation. The notion
that mitochondrial metabolism is necessary for T cell activation
is further supported by the observations that chronically acti-
vated T cells isolated from mouse model of lupus are dependent
on mitochondrial metabolism and peripheral blood lymphocytes
from patients with lupus have increased mitochondrial meta-
bolism and ROS production (Gergely et al., 2002; Wahl et al.,
2010).
Differential Metabolic Pathways Regulate CD4+ T Cell
Differentiation
Once activated, T cells differentiate into different Te subsets
ranging from pro-inflammatory T helper 1 (Th1), Th17, and
Th22 cells to suppressive regulatory T (Tregs) cells to curtail
infection. Traditionally, these subsets have been classified by
specific transcription factor activation. Emerging data indicate
that these different T cell subsets have distinctivemetabolic phe-
notypes that can promote T cell subset differentiation. Perhaps
the best-studied subsets are Treg and Th17 cells, which have
different metabolic profiles that are essential to establish their
phenotype. Tregs have elevated levels of oxidative phosphoryla-
tion and decreased glycolytic flux compared to Th17 cells (Mi-
chalek et al., 2011).Immunity 42, March 17, 2015 ª2015 Elsevier Inc. 411
Figure 4. Mitochondrial Signaling Is
Required for T Cell Activation
Upon binding of the TCR with MHC, numerous
signaling cascades are activated. One of the
activated pathways MYC activates an anabolic
metabolic program that increases uptake of
glucose and glutamine and allows for the cells to
meet the increased metabolic demands of prolif-
eration and induction of an adaptive immune
response (blue). Importantly, in this model, meta-
bolism works to sustain cellular activity required
for a proper immune response. However, the
mitochondria also alter cellular signaling upon
ligation of the TCR. Specifically, mitochondrial
ROS production following TCR stimulation is
required for proper activation of NFAT and IL-2
production (orange). In this way, the mitochondrial
signaling and metabolism are required for proper
T cell activation.
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to be due to increased AMPK-dependent fatty-acid oxidation
(MacIver et al., 2011; Michalek et al., 2011). Pharmacologically
attenuating fatty-acid oxidation by etomoxir impaired Treg differ-
entiation, but did not affect other CD4 helper subsets in vitro.
By contrast, Th17 cells engage in de novo fatty-acid synthesis
that is necessary for the Th17 phenotype. Pharmacologic and
genetic inhibition of the enzyme acetyl-CoA carboxylase 1
(ACC1), the enzyme that catalyzes the first step of de novo
fatty-acid synthesis, impaired Th17 cell differentiation, and pro-
moted Tregs in vitro and in vivo, as well as attenuated EAE in
mice (Berod et al., 2014). It is presently not clear why fatty-acid
oxidation versus synthesis appears to be a checkpoint in the
T cell-fate decision between Treg and Th17 cells.
Increased glycolytic metabolism in Th17 cells also appears to
be important to maintaining their Th17 lineage state. Pharmaco-
logical inhibition of glucose metabolism by administering 2-de-
oxyglucose attenuated Th17 cell development and interestingly
promoted Treg cell development and diminished pathology in
a Th17-dependent experimental autoimmune encephalomyelitis
(EAE) (Shi et al., 2011). The increase in glycolysis observed in
Th17 cells is due to an increase in HIF-1, and mice with T cells
deficient in HIF-1a display diminished Th17 cells, increased
Treg cells, and resistance to EAE (Dang et al., 2011; Shi et al.,
2011). Further evidence comes from the observation that the
HIF-1 target PDHK1 is expressed in Th17 cells, but not in
Treg cells, and diminishing PDHK1, the negative regulator of py-
ruvate dehydrogenase (PDH), suppressed Th17 formation and
increased Treg formation in vitro (Gerriets et al., 2014). PDH is
necessary for converting pyruvate to acetyl-CoA in mitochon-
drial matrix and increasing PDHK1 reduces PDH activity thus
limiting mitochondrial acetyl-CoA availability. These data are
supported in vivo by the observation that pharmacologic inhibi-
tion of PDHK by dichloracetate (DCA) in mice diminishes Th17
and promotes Tregs resulting inhibition of Th17 dependent coli-
tis and EAE pathologies.
The mechanisms by which diminishing mitochondrial meta-
bolism and/or enhancing glycolysis resulting in increased cells
with concomitant decreased Treg cells is not fully understood.
It is possible that the decrease in mitochondrial metabolism412 Immunity 42, March 17, 2015 ª2015 Elsevier Inc.concomitantly with an increase in glycolysis diminishes ROS
through unknown mechanisms to promote Th17 differentiation.
It is important to note that the ROS regulation of Th17/Treg
axis has yet to be confirmed genetically. This is imperative
because pharmacological inhibition of these pathways can
affect multiple cell types, and conclusions drawn from these
studies can be difficult to interpret. For example, unexpectedly
fatty-acid oxidation inhibition by etomoxir reduces disease
severity of EAE (Shriver and Manchester, 2011). On the basis
of in vitro findings, fatty-acid oxidation inhibition is predicted to
decrease Tregs cells, thus exacerbating EAE. Nevertheless,
collectively these emerging metabolic studies suggest that mito-
chondrial metabolism function dictates the different inflamma-
tory and suppressive CD4+ T helper lineages.
Mitochondrial Metabolism Regulates CD8+ Memory T
Cell Formation
During the resolution phase of an infection, the majority of CD8+
Te cells undergo cell death with the survival of a few long-lived
CD8+ memory T cells (Tm). Re-infection with a pathogen con-
taining similar antigens allows these Tm cells to be reactivated
and rapidly expand into T cells to quickly control the infection.
Tm cells are not rapidly proliferating and thus do not have high
anabolic requirements. They efficiently catabolize nutrients to
generate ATP to maintain long-term cell survival. Thus, Tm cells
have a contrasting metabolic profile compared to Tm cells
(Figure 5). Tm cells display increased mitochondrial number
and spare respiratory capacity, which is fueled by fatty-acid
oxidation to generate copious amount of ATP (Pearce et al.,
2009; van der Windt et al., 2012). Fatty-acid oxidation generates
almost three times more ATP than glucose oxidation by mito-
chondria. The source of fatty acids in Tm cells is not extracellular
but rather internal lysosomal stores. Tm cells display reduced
surface expression of CD36, necessary for fatty-acid uptake,
compared with Te cells and engage in de novo lipogenesis and
store lipids in lysosomes (O’Sullivan et al., 2014). Tm cells utilize
lysosomal acid lipase (LAL) in Tm cells to liberate free fatty
acids from storage for the robust fatty-acid oxidation in
the mitochondria. Thus, Tm cells appear to utilize a ‘‘futile cycle’’
whereby fatty-acid synthesis occurs concurrently with fatty-acid
Figure 5. CD8+ Effector T Cells Display a
Distinct Mitochondrial Metabolic Profile
Compared to CD8+ Memory T Cells
Upon T cell activation, effector T cells rapidly in-
crease uptake of glucose and glutamine, which is
utilized to produce the ATP and cellular building
blocks (NADPH and fatty acids) required for pro-
duction of clonal T cells. The mitochondria in
effector T cells functions as an anabolic hubwhere
TCA cycle intermediates are shuttled into the
cytoplasm to promote production of increase
cellular biomass. In contrast, memory T cells utilize
fatty-acid catabolism to efficiently generate ATP to
fuel cellular survival.
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T cells. The biochemical basis as to how and why Tm cells
conduct concurrent fatty-acid synthesis and fatty-acid oxidation
is not fully understood, because most cells utilize regulatory
mechanisms that prevent this inefficiency. One possibility is
that the availability of fatty acids from the extracellular environ-
ment in vivo might differ depending on the tissues where they
reside; therefore, Tm cells continuously store lipids that can be
utilized for fatty-acid oxidation. The importance of fatty-acid
oxidation for Tm cells is bolstered by the observations that di-
minishing or enhancing AMPK, a positive regulator of fatty-acid
oxidation, decreases or increases formation of memory T cells
(MacIver et al., 2011; Pearce et al., 2009; Rolf et al., 2013; Tama´s
et al., 2010). Further evidence supporting the importance of
mitochondrial metabolism comes from the observation that
increasing or decreasing glycolytic flux, which reciprocally mod-
ulates mitochondrial metabolism, results in enhanced or dimin-
ished generation of memory T cells, respectively (Sukumar
et al., 2013). Although there is mounting evidence that mitochon-
drial metabolism maintains the memory T cell phenotype, it re-
mains unknownwhy this is andwhethermitochondria participate
in cell signaling necessary to establish the memory T cell pheno-
type.
Similar to T cells, B cells also undergo major transitions in
their metabolic profiles as they transition from naive quiescent
cells to anabolic proliferative cells. Upon activation, B cells
greatly enhance glucose and glutamine metabolism during
clonal expansion comparable to T cells (Doughty et al., 2006;
Garcia-Manteiga et al., 2011; Le et al., 2012). Along with these
changes in metabolism, B cell receptor (BCR) activation is regu-
lated by ROS (Capasso et al., 2010; Singh et al., 2005). Specif-
ically, BCR ligation stimulates calcium release into the cytoplasm
that promotes ROS production and inactivation of receptor-
coupled phosphates, allowing for activation of downstream
signaling pathways. Depending on the magnitude of the ROS
pulse, there is increased duration of BCR signaling and
enhanced activation of downstream signaling pathways (Singh
et al., 2005). Initially, the cytosolic NADPH oxidases were sur-
mised to be source of ROS for B cell function. However, new
data from primary B cells suggests that early ROS production
by NADPH oxidases is dispensable for BCR signaling (Richards
and Clark, 2009; Wheeler and Defranco, 2012). Instead, long-Immunity 4term elevations in ROS levels, potentially
driven by increased production of mito-
chondrial ROS, are required for down-stream BCR signaling and cellular proliferation in response to
BCR cross-linking (Wheeler and Defranco, 2012). Along with
ROS signaling, new studies also suggest that other mitochon-
drial-derived molecules have important roles in B cell activation
and effector function. Recent studies have suggested that
plasma cells produce increased levels of phospholipids when
compared to naive B cells, and plasma cell differentiation is
dependent on mitochondrial citrate conversion to acetyl-CoA
and oxaloacetate in the cytoplasm (Dufort et al., 2014; Fagone
et al., 2007). Although the evidence is incomplete, these new
studies indicate that mitochondrial metabolism is altered during
B cell activation and plasma cell development. Future studieswill
delineate whether mitochondria metabolism is essential in
driving differential B cell function in a manner similar to T cells.
Concluding Remarks
The mammalian immune response is extremely complex,
requiring the coordination of multiple organ systems and a large
variety of cells within those organs. These immune cells are so
effective because they are able to rapidly respond to the stress
of infection through activation and often proliferation, differenti-
ation, and finally cell death. Furthermore, during an immune
response, immune cells must decide to participate as an effector
cell promoting inflammation or a suppressor cell ensuring
adequate control of the inflammation. Within the capacity of an
effector cell, various cells acquire more specific abilities neces-
sary to fighting specific types of infections be it viral, bacterial,
or parasitic. Thus, a rapid change in cell fate is absolutely essen-
tial to immunity. Although decades of study have shown that
direct signaling from the cell surface to the nucleus is critical to
these cell-fate decisions, more recent work has shown that these
signaling pathways often include detours that transmit through
metabolic machinery to ensure cooperation of metabolism in
the cell-fate decision (Pearce et al., 2013) It is becoming clear
that cellular metabolism plays a highly active role in determining
cellular destiny in the immune system—in other words, we are
learning that the immune cell is what it eats.
In this review, we highlight the mitochondrion as a central
hub of immune-cell regulation. We outline that in immune cells,
mitochondria participate in signaling through ROS production,
metabolite availability, and by physically acting as scaffolding
for protein interaction. Mitochondrial signals appear to be2, March 17, 2015 ª2015 Elsevier Inc. 413
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Reviewnecessary for the immune cell to fulfill its specific role in the im-
mune response in both innate and adaptive settings to a variety
of intruders. Ironically, this organelle of bacterial origin has es-
tablished itself as a major conductor of the defense of the organ-
ism from invaders such as bacteria.
The studies we have discussed open several avenues for
future investigation. First, we are lacking important mechanistic
detail regarding the role of mitochondria in immune cells.
Some questions include: what are the critical mitochondrial
ROS targets in immune cell activation? Howdo the peroxisomes,
ER, and mitochondria communicate to optimally regulate im-
mune responses? Does availability of TCA cycle intermediates
like acetyl-CoA, alpha-ketoglutarate, and citrate alter immune
cell activation similar to succinate? If so, how? Second, several
of the mechanisms discussed in this review are lacking in vivo
evidence. Future study should use genetics and targeted small
molecules to show that mitochondria are indeed important in
the setting of a complex organismal immune response.
Lastly, the essential question remains whether targeting mito-
chondrial metabolism in humans will allow for modulation of the
immune response in disease. We are very interested in deter-
mining the specific metabolic fuels and enzymes that sustain
mitochondrial function in the immune response, as identification
of these major crutches of mitochondrial function within immune
cells might allow for development of small molecules for immune
therapy. For example, the anti-diabetic drug metformin is being
utilized an immunomodulator for tuberculosis (Singhal et al.,
2014). It is not clear what the target of metformin in immune cells
is but the anti-tumor effects of metformin are through inhibiting
mitochondrial complex I (Wheaton et al., 2014). Moreover,
Bz-423, a small-molecule inhibitor of themitochondrial ATP-syn-
thase, arrested established graft versus host disease (GVHD) in
several bone marrow transplant models without affecting he-
matopoietic engraftment or lymphocyte reconstitution (Gatza
et al., 2011). Beyond pharmaceuticals, modulation of total calo-
rie availability, as well as type of calorie availability and subse-
quent support of specific cellular metabolic pathways, may
also prove to be a useful method of immune modulation.
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